Aflibercept in wet AMD: specific role and optimal use

References

• Chappelow AV Kaiser PK Neovascular age-related macular degeneration: potential therapies Drugs 2008 68 8 1029 1036 18484796
   PubMed Web of Science ®Google Scholar
• La Cour M Kiilgaard JF Nissen MH Age-related macular degeneration: epidemiology and optimal treatment Drugs Aging 2002 19 2 101 133 11950377
   PubMed Web of Science ®Google Scholar
• Bloch SB Larsen M Munch IC Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000–2010 Am J Ophthalmol 2012 153 2 209 213 22264944
   PubMed Web of Science ®Google Scholar
• Campa C Costagliola C Incorvaia C Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications Mediators Inflamm 2010 2010
   Web of Science ®Google Scholar
• Stewart MW The expanding role of vascular endothelial growth factor inhibitors in ophthalmology Mayo Clin Proc 2012 87 1 77 88 22212972
   PubMed Web of Science ®Google Scholar
• Stewart MW Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept Clin Ophthalmol 2012 6 1175 1186 22973088
   PubMedGoogle Scholar
• Ferrara N Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 8 2004 25 4 581 611 15294883
   PubMed Web of Science ®Google Scholar
• Alitalo K Tammela T Petrova TV Lymphangiogenesis in development and human disease Nature 2005 438 946 953 16355212
   PubMed Web of Science ®Google Scholar
• Lee S Jilani SM Nikolova GV Carpizo D Iruela-Arispe ML Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors J Cell Biol 2005 169 681 691 15911882
   PubMed Web of Science ®Google Scholar
• Leung DW Cachianes G Kuang WJ Goeddel DV Ferrara N Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246 1306 1309 2479986
   PubMed Web of Science ®Google Scholar
• Alon T Hemo I Itin A Stone J Keshet E Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity Nat Med 1995 1 1024 1028 7489357
   PubMed Web of Science ®Google Scholar
• Gerber HP Dixit V Ferrara N Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells J Biol Chem 1998 273 13313 13316 9582377
   PubMed Web of Science ®Google Scholar
• Carmeliet P Angiogenesis in life, disease and medicine Nature 2005 438 932 936 16355210
   PubMed Web of Science ®Google Scholar
• Rosenstein JM Krum JM New roles for VEGF in nervous tissue – beyond blood vessels Exp Neurol 2004 187 246 253 15144851
   PubMed Web of Science ®Google Scholar
• Jin K Zhu Y Sun Y Mao XO Xie L Greenberg DA Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo Proc Natl Acad Sci U S A 2002 99 11946 11950 12181492
   PubMed Web of Science ®Google Scholar
• Asahara T Takahashi T Masuda H VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells EMBO J 1999 18 3964 3972 10406801
   PubMed Web of Science ®Google Scholar
• Roberts WG Palade GE Neovasculature induced by vascular endothelial growth factor is fenestrated Cancer Res 1997 57 765 772 9044858
   PubMed Web of Science ®Google Scholar
• Roberts WG Palade GE Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor J Cell Sci 1995 108 6 2369 2379 7673356
   PubMed Web of Science ®Google Scholar
• Monsky WL Fukumura D Gohongi T Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor Cancer Res 1999 59 4129 4135 10463618
   PubMed Web of Science ®Google Scholar
• Gragoudas ES Adamis AP Cunningham ETJr Feinsod M Guyer DR VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group for neovascular age-related macular degeneration N Engl J Med 2004 351 2805 2816 15625332
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Chakravarthy U Adamis AP Year 2 efficacy results of 2 randomised controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 2006 113 1508. e1 e25 16828500
   PubMed Web of Science ®Google Scholar
• Singerman LJ Masonson H Patel M Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol 2008 92 1606 1611 18614570
   PubMed Web of Science ®Google Scholar
• Frampton JE Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration Drugs Aging 2013 30 5 331 358 23539234
   PubMed Web of Science ®Google Scholar
• Martin DF Maguire MG Ying GS Grunwald JE Fine SL Jaffe GJ CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 2011 364 20 1897 1908 21526923
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Martin DF Maguire MG Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 2012 119 7 1388 1398 22555112
   PubMed Web of Science ®Google Scholar
• Ahfat FG Zaidi FH Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN Eye (Lond) 3 2013 27 3 289 290 23485959
   PubMed Web of Science ®Google Scholar
• Costagliola C Romano M Corte MD Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina Oct 2009 29 9 1227 1234
   Google Scholar
• Steinbrook R The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration N Eng J Med 2006 355 1409 1412
   PubMed Web of Science ®Google Scholar
• Meyer CH Krohne TU Holz FG Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans Retina 2011 31 9 1877 1884 21738089
   PubMed Web of Science ®Google Scholar
• Conrad PW Zacks DN Johnson MW Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration Clin Ophthalmol 2008 2 4 727 733 19668423
   PubMedGoogle Scholar
• Rosenfeld PJ Brown DM Heier JS MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006 355 1419 1431 17021318
   PubMed Web of Science ®Google Scholar
• Brown DM Kaiser PK Michels M ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 2006 355 1432 1444 17021319
   PubMed Web of Science ®Google Scholar
• Brechner RJ Rosenfeld PJ Babish JD Caplan S Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file Am J Ophthalmol 2011 151 5 887 895. e1 21310390
   PubMed Web of Science ®Google Scholar
• Bevacizumab prescribing information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf Accessed July 24, 2013
   Google Scholar
• Semeraro F Morescalchi F Parmeggiani F Arcidiacono B Costagliola C Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration Curr Vasc Pharmacol 2011 9 5 629 646 21470108
   PubMed Web of Science ®Google Scholar
• Costagliola C Agnifili L Arcidiacono B Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration Expert Opin Biol Ther 2012 12 10 1299 1313 22866908
   PubMed Web of Science ®Google Scholar
• Boyer DS Heier JS Brown DM A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 2009 116 9 1731 1739 19643495
   PubMed Web of Science ®Google Scholar
• Regillo CD Brown DM Abraham P Randomised, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1 Am J Ophthalmol 2008 145 239 248 18222192
   PubMed Web of Science ®Google Scholar
• Michels M Francom S Wilson L Systemic safety and risk factors associated with intravitreal ranibizumab in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) 26th Annual Meeting of the American Society of Retina Specialists October 11–15, 2008 Maui, HI, USA
   Google Scholar
• Schmidt-Erfurth U Eldem B Guymer R EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 2011 118 5 831 839 21146229
   PubMed Web of Science ®Google Scholar
• Lalwani GA Rosenfeld PJ Fung AE A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol Jul 2009 148 1 43 58
   Google Scholar
• Papadopoulos N Martin J Ruan Q Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 2012 15 2 171 185 22302382
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration FDA approves Eylea for eye disorder in older people 11 18 2011 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm Accessed December 4, 2011
   Google Scholar
• Dixon JA Oliver SC Olson JL Mandava N VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 2009 18 10 1573 1580
   PubMed Web of Science ®Google Scholar
• Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye Drugs R D 2008 9 4 261 269 18588357
   PubMed Web of Science ®Google Scholar
• Vaisman N Gospodarowicz D Neufeld G Characterization of the receptors for vascular endothelial growth factor J Biol Chem 1990 265 19461 19466 2246236
   PubMed Web of Science ®Google Scholar
• Jakeman LB Armanini M Philips HS Ferrara N Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis Endocrinology 1993 133 848 859 7688292
   PubMed Web of Science ®Google Scholar
• De Vries C Escobedo JA Ueno H Houck K Ferrara N Williams LT The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science 1992 255 989 991 1312256
   PubMed Web of Science ®Google Scholar
• Shibuya M Yamaguchi S Yamane A Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family Oncogene 1990 5 4 519 524 2158038
   PubMed Web of Science ®Google Scholar
• Matthews W Jordan CT Gavin M Jenkins NA Copeland NG Lemischka IR A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit Proc Natl Acad Sci U S A 1991 88 9026 9030 1717995
   PubMed Web of Science ®Google Scholar
• Terman BI Carrion ME Kovacs E Rasmussen BA Eddy RL Shows TB Identification of a new endothelial cell growth factor receptor tyrosine kinase Oncogene 1991 6 1677 1683 1656371
   PubMed Web of Science ®Google Scholar
• Pajusola K Aprelikova O Korhonen J FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines Cancer Res 1992 52 5738 5743 1327515
   PubMed Web of Science ®Google Scholar
• Karkkainen MJ Makinen T Alitalo K Lymphatic endothelium: a new frontier of metastasis research Nat Cell Biol 2002 4 E2 E5 11780131
   PubMed Web of Science ®Google Scholar
• Stewart MW Rosenfeld PJ Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 2008 92 5 667 668 18356264
   PubMed Web of Science ®Google Scholar
• Stewart MW What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model Eye Reports 2011 1 e5
   Google Scholar
• Holash J Davis S Papadopoulos N VEGF-Trap: a VEGF blocker with potent antitumor effects PNAS 2002 99 17 11392 11398
   Web of Science ®Google Scholar
• Rakic JM Lambert V Munaut C Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization Invest Ophthalmol Vis Sci 2003 44 4 1732 1739 12657615
   PubMed Web of Science ®Google Scholar
• Saishin Y Saishin Y Takahashi K VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol May 2003 195 2 241 248
   Google Scholar
• EYLEA™ (aflibercept) injection: US prescribing information Tarrytown, NY, USA Regeneron Pharmaceuticals, Inc Available from: http://www.regeneron.com/Eylea/eylea-fpi.pdf Accessed April 2, 2012
   Google Scholar
• Nguyen QD Shah SM Hafiz G CLEAR-AMD 1 Study Group A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration Ophthalmology 2006 113 1522. e1 1532. e14 16876249
   PubMed Web of Science ®Google Scholar
• Do DV Nguyen QD Browning DJ Results of a phase I study of intravitreal VEGF Trap in subjects with diabetic macular edema: the CLEAR-IT DME Study IOVS 2007 48 ARVO E-abstract 1430/B486
   Google Scholar
• Nguyen QD Shah SM Browning DJ A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration Ophthalmology 2009 116 2141 2148 19700196
   PubMed Web of Science ®Google Scholar
• Brown DM Heier JS Ciulla T CLEAR-IT 2 Investigators Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration Ophthalmology 2011 118 6 1089 1097 21640257
   PubMed Web of Science ®Google Scholar
• Heier JS Boyer D Nguyen QD CLEAR-IT 2 Investigators The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fxed dosing Ophthalmology 2011 118 1098 1106 21640258
   PubMed Web of Science ®Google Scholar
• Cantrill HL The diabetic retinopathy study and the early treatment diabetic retinopathy study International Ophthalmology Clinics 1984 24 4 13 29 6389409
   PubMedGoogle Scholar
• Stewart MW Rosenfeld PJ Penha FM Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye) Retina 2012 32 3 434 457 22374154
   PubMed Web of Science ®Google Scholar
• Heier JS Brown DM Chong V VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 2012 119 12 2537 2548 23084240
   PubMed Web of Science ®Google Scholar
• Sho K Takahashi K Yamada H Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics Arch Ophthalmol 2003 121 10 1392 1396 14557174
   PubMedGoogle Scholar
• Squirrell DM Bacon JF Brand CS To investigate the prevalence of polypoidal choroidal vasculopathy in presumed age-related peripapillary subretinal neovascular membranes Clin Experiment Ophthalmol 2009 37 4 368 372 19594563
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals, Inc Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) injection in wet AMD show sustained improvement in visual acuity [press release] Tarrytown, NY Regeneron Pharmaceuticals, Inc 12 5 2011 Available from: http://investor.regeneron.com/releasedetail.cfm?releaseid=629800 Accessed June 27, 2013
   Google Scholar
• Regeneron Pharmaceuticals, Inc Bayer and Regeneron report positive top-line results of two phase 3 studies with VEGF Trap-Eye in wet age-related macular degeneration [press release] Tarrytown, NY Regeneron Pharmaceuticals, Inc 11 22 2010 Available from: http://newsroom.regeneron.com/releasedetail.cfm?releaseid=532099 Accessed June 27, 2013
   Google Scholar
• Antonetti DA Barber AJ Hollinger LA Wolpert EB Gardner TW Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonulaoccluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors J Biol Chem 1999 274 23463 23476 10438525
   PubMed Web of Science ®Google Scholar
• Pierce EA Avery RL Foley ED Aiello LP Smith LE Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization Proc Natl Acad Sci U S A 1995 92 905 909 7846076
   PubMed Web of Science ®Google Scholar
• Rinaldi M Chiosi F Dell’Omo R Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study Br J Clin Pharmacol 2012 74 6 940 946 22486651
   PubMed Web of Science ®Google Scholar
• Bethke W For DME, one size does not fit all [webpage on the Internet] Review of Opthalmology 8 8 2011 Available from: http://www.revophth.com/content/i/1599/c/29625/ Accessed April 05, 2013
   Google Scholar
• Clinical Trials Available from: http://www.clinicaltrials.gov/ Accessed July 24, 2013
   Google Scholar
• Nguyen QD Shah SM Heier JS READ-2 Study Group Primary endpoint (six-months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study Ophthalmology 2009 116 2175 2181 19700194
   PubMed Web of Science ®Google Scholar
• Nguyen QD Shah SM Khwaja AA READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study Ophthalmology 2010 117 2146 2151 20855114
   PubMed Web of Science ®Google Scholar
• Massin P Bandello F Garweg JG Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 2010 33 2399 2405 20980427
   PubMed Web of Science ®Google Scholar
• Mitchell P Bandello F Schmidt-Erfurth U RESTORE Study Group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 2011 118 615 625 21459215
   PubMed Web of Science ®Google Scholar
• Nguyen QD Brown DM Marcus DM et al; RISE RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 2012 119 789 801 22330964
   PubMed Web of Science ®Google Scholar
• Boyer DS Rundle AC Zhang J Hopkins JJ Ehrlich JS Long-term efficacy and safety of ranibizumab in diabetic macular edema (DME): 36-month results from RISE and RIDE, two phase III clinical trials 45th Annual Scientific Meeting of the Retina Society October 5, 2012 Washington DC, USA
   Google Scholar
• Do DV Schmidt-Erfurth U Gonzalez VH The DAVINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema Ophthalmology 2011 118 1819 1826 21546089
   PubMed Web of Science ®Google Scholar
• Do DV Nguyen QD Boyer D DAVINCI Study Group One-year outcomes of the DAVINCI study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 2012 119 1658 1665 22537617
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals Inc Regeneron and Bayer Initiate Phase 3 Trial of EYLEA®(aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia Available from: http://investor.regeneron.com/releasedetail.cfm?ReleaseID=741127 Accessed July 24, 2013
   Google Scholar
• Regeneron Announces FDA Approval of EYLEA®(aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion Available from http://investor.regeneron.com/releasedetail.cfm?releaseid=708835 Accessed July 24, 2013
   Google Scholar
• Boyer D Heier J Brown DM Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study Ophthalmology 2012 119 1024 1032 22440275
   PubMed Web of Science ®Google Scholar
• Brown DM Heier JS Clark LW Intravitreal aflibercept injection for macular edema secondary to central vein occlusion: 1-year results from the phase 3 COPERNICUS study Am J Ophthalmol 2013 155 429 437 23218699
   PubMed Web of Science ®Google Scholar
• Holz FG Roider J Ogura Y VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 2013 97 278 284 23298885
   PubMed Web of Science ®Google Scholar
• Holz FG Ogura Y Roider J Intravitreal aflibercept injection for macular edema in central retinal vein occlusion: 1-year results of the phase 3 GALILEO Study [Poster 6929; online] Available from: https://www.abstractsonline.com
   Google Scholar
• US Food and Drug Administration Eylea US Food and Drug Administration Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf Accessed June 27, 2013
   Google Scholar
• Schaal S Kaplan HJ Tezel TH Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008 115 12 2199 2205 18930553
   PubMed Web of Science ®Google Scholar
• Forooghian F Cukras C Meyerle CB Chew EY Wong WT Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration Retina 2009 29 6 723 731 19516114
   PubMed Web of Science ®Google Scholar